Max Planck opens big neurosciences institute; NeurogesX lays off staffers ahead of PhIII; Fiscal cliff fears rattle researchers;

Conversation on Twitter :

 @FierceBiotech: From FierceBiotechIT.com: Database aims to speed discoveries for blood cancer treatments. Report | Follow @FierceBiotech

 @JohnCFierce: Another figure for "average" drug R&D costs--1.2B sterling--biotech efficient source of new drugs, via FT. More (sub. req.) | Follow @JohnCFierce

 @RyanMFierce: Say what? Reuters is making some noise about the neglected $4.6B market for hearing-loss drugs. Story | Follow @RyanMFierce

> After 6 years of work and millions in costs, the Max Planck Florida Institute of Neuroscience is officially open and in the business of doing research for depression, Alzheimer's and other hard-to-hit diseases. Report

> Concentrating on its lead pain drug, NeurogesX says it will lay off 9 staffers. The biotech is laying the foundation for a Phase III study of NGX-1998, its next-gen version of Qutenza. Story

> Hoping to gain the inside track on its R&D program for an experimental neuropathy drug, DARA Biosciences has requested orphan drug status for KRN5500. Story

Pharma News

@FiercePharma: ICYMI: Pfizer is cutting its US primary care sales force. $$ down in that group post-Lipitor--Dow Jones. News | Follow @FiercePharma

> Is pharma ready to capitalize on vitamin market shakeup? Report

> Pfizer sharpens job-cutting ax for U.S. sales layoffs. News

> Bill suggests wholesale pricing to fight drug shortages. Story

Medical Device News

 @FierceMedDev: NanoString draws $15.3M Series E for cancer diagnostics test launch. Story | Follow @FierceMedDev

@MarkHFierce: SCOTUS will consider whether human genes can be patented. The case has profound implications for the future of Dx. More | Follow @MarkHFierce

 @DamianFierce: A European nonprofit says Big Pharma needs to keep a closer eye on its CRO partners, and ACRO cries foul. Story | Follow @DamianFierce

> Medtronic snags CE mark for critical-care glucose monitor. Report

> FDA to mull reclassification for some circulatory system devices. Item

Biotech IT News

> Stanford to rival Broad Institute with Big Data-focused genomics center. Report

> Study: Genomics, outsourcing fuel double-digit growth in bioinformatics. Article

> Social media, iPhone app aid efforts to crowdsource disease surveillance. News

> Why Big Data alone lacks the punch pharma needs. Story

CRO News

> Indian regulators want crackdown on unethical CROs. Report

> CROs lack oversight, report says; ACRO cries foul. Story

> AMRI shutters R&D site, moving jobs to Singapore. News

> Parexel partners with Taiwan hospital for drug development. More

And Finally… Alarmed by the looming prospect of a severe cut in the NIH budget if Congress and the president sail over the fiscal cliff, the Associated Medical Schools of New York called on the state's Congressional delegation to preserve research funding. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.